NCT00402831View on ClinicalTrials.gov

ProQuad® Intramuscular vs Subcutaneous

PHASE3CompletedINTERVENTIONAL

Enrollment

405

Participants

Timeline

Start Date

October 6, 2006

Primary Completion Date

May 11, 2007

Study Completion Date

May 11, 2007

Conditions

MeaslesMumpsRubellaVaricella

Interventions

BIOLOGICAL

ProQuad®

Each dose (0.5 mL) contains live attenuated versions of measles virus Enders' Edmonston strain, mumps virus Jeryl Lynn™ (Level B) strain, rubella virus Wistar RA 27/3 strain, and varicella virus Oka/Merck strain.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00402831 - ProQuad® Intramuscular vs Subcutaneous | Biotech Hunter | Biotech Hunter